82
Participants
Start Date
November 30, 2014
Primary Completion Date
December 3, 2018
Study Completion Date
December 3, 2018
PF-02341066
PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously
PD-0325901
PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.
Binimetinib
Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days
Oxford University Hospital NHS Trust, Oxford
Collaborators (2)
Queen's University, Belfast
OTHER
Oxford University Hospitals NHS Trust
OTHER
Velindre NHS Trust
OTHER_GOV
University Hospital, Antwerp
OTHER
Hospital Vall d'Hebron
OTHER
Saint Antoine University Hospital
OTHER
European Georges Pompidou Hospital
OTHER
Pfizer
INDUSTRY
University of Turin, Italy
OTHER
Belfast Health and Social Care Trust
OTHER
Beaumont Hospital
OTHER
European Commission
OTHER
Array BioPharma
INDUSTRY
University of Paris 5 - Rene Descartes
OTHER
University of Oxford
OTHER